Following a request received from the company, NICE will be undertaking an evaluation of Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]. The evaluation is expected to start during early-October 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during late-November 2023.